1. Home
  2. XYLO vs PHIO Comparison

XYLO vs PHIO Comparison

Compare XYLO & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XYLO
  • PHIO
  • Stock Information
  • Founded
  • XYLO 1999
  • PHIO 2011
  • Country
  • XYLO Israel
  • PHIO United States
  • Employees
  • XYLO N/A
  • PHIO N/A
  • Industry
  • XYLO
  • PHIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • XYLO
  • PHIO Health Care
  • Exchange
  • XYLO NYSE
  • PHIO Nasdaq
  • Market Cap
  • XYLO 2.3M
  • PHIO 2.3M
  • IPO Year
  • XYLO N/A
  • PHIO N/A
  • Fundamental
  • Price
  • XYLO $3.15
  • PHIO $2.61
  • Analyst Decision
  • XYLO
  • PHIO Strong Buy
  • Analyst Count
  • XYLO 0
  • PHIO 1
  • Target Price
  • XYLO N/A
  • PHIO $36.00
  • AVG Volume (30 Days)
  • XYLO 17.6K
  • PHIO 30.8K
  • Earning Date
  • XYLO 12-27-2024
  • PHIO 11-14-2024
  • Dividend Yield
  • XYLO N/A
  • PHIO N/A
  • EPS Growth
  • XYLO N/A
  • PHIO N/A
  • EPS
  • XYLO N/A
  • PHIO N/A
  • Revenue
  • XYLO $57,642,000.00
  • PHIO N/A
  • Revenue This Year
  • XYLO N/A
  • PHIO N/A
  • Revenue Next Year
  • XYLO N/A
  • PHIO N/A
  • P/E Ratio
  • XYLO N/A
  • PHIO N/A
  • Revenue Growth
  • XYLO N/A
  • PHIO N/A
  • 52 Week Low
  • XYLO $2.70
  • PHIO $2.17
  • 52 Week High
  • XYLO $10.43
  • PHIO $10.35
  • Technical
  • Relative Strength Index (RSI)
  • XYLO 39.41
  • PHIO 48.74
  • Support Level
  • XYLO $3.11
  • PHIO $2.58
  • Resistance Level
  • XYLO $3.90
  • PHIO $2.91
  • Average True Range (ATR)
  • XYLO 0.31
  • PHIO 0.21
  • MACD
  • XYLO -0.05
  • PHIO 0.01
  • Stochastic Oscillator
  • XYLO 2.94
  • PHIO 26.76

About XYLO XYLO TECHNOLOGIES LTD

Xylo Technologies Ltd is an Israel-based medical device company. The company is engaged in the development, manufacturing, and marketing of direct vision systems for minimally invasive medical procedures and safety systems for drones and the electric vehicle (EV) sector. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incision-less treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company operates in five segments namely, E-Commerce, Online Advertising & Internet Traffic Routing, Online Event Management, Corporate, and others. The company's geographical segments include the United States, Europe, Great Britain, Israel, Canada, Asia, and others.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Share on Social Networks: